Cystatin and Early AKI Detection Contrast Induced Acute Kidney Injury
Clinical Utility of Cystatin C in the Early Detection of Contrast Induced Acute Kidney Injury
1 other identifier
observational
100
1 country
4
Brief Summary
To determine the clinical utility of serum cystatin C in early detection of acute kidney injury (AKI).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2025
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 11, 2025
CompletedFirst Submitted
Initial submission to the registry
September 25, 2025
CompletedFirst Posted
Study publicly available on registry
September 30, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
February 28, 2027
ExpectedSeptember 30, 2025
September 1, 2025
12 months
September 25, 2025
September 25, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Incidence of AKI when sCr is used compared to when sCyC is used 24-48 hours after contract media and at 7-10 days follow-up
10 days
Secondary Outcomes (1)
Change from baseline in eGFRcr compared to change from baseline in eGFRcys 24-48 hours after contrast media and at 7 to 10 days follow-up
10 days
Eligibility Criteria
Study participants will be a cohort of inpatients with CKD. Eligible study participants, as defined by the inclusion criteria, will be consented at Morton Plant North Bay Hospital, Mease Countryside Hospital, and Morton Plant Hospital and St. Anthony's Hospital.
You may qualify if:
- Subjects ages 18 years and above
- Inpatients with CKD (Figure 1)
- Order for CT imaging study or coronary angiography with isohexol Omnipaque) contrast media.
- Pre and post contrast available
- All races and ethnicity of patients are eligible. We expect to analyze approximately equal number of men and women in this study.
You may not qualify if:
- Preexisting dialysis
- Patients under the age of 18 years
- Pregnancy
- Incarcerated individuals
- Patients with impaired cognition and unable to follow consent procedures
- Recent exposure to CM (within 2 days before/after procedure)
- Cardiac shock
- Medications that affect biomarkers, including corticosteroids, lfamethoxazoletrimethoprim
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (4)
Morton Plant Hospital
Clearwater, Florida, 33756, United States
Morton Plant North Bay Hospital
New Port Richey, Florida, 34652, United States
Mease Countryside Hospital
Safety Harbor, Florida, 34695, United States
St. Anthony's Hospital
St. Petersburg, Florida, 33705, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 25, 2025
First Posted
September 30, 2025
Study Start
March 11, 2025
Primary Completion
February 28, 2026
Study Completion (Estimated)
February 28, 2027
Last Updated
September 30, 2025
Record last verified: 2025-09